伊马替尼与干扰素联合羟基脲对慢性粒细胞白血病的疗效

The Curative Effect of Imatinib and Interferon Combined With Hydroxyurea for Chronic Myelogenous Leukemia

目的研究分析伊马替尼与干扰素联合羟基脲治疗慢性粒细胞白血病的疗效。方法选取我院收治的慢性粒细胞白血病患者68例作为研究对象。将患者随机分为观察组与对照组。观察组患者给予伊马替尼治疗,对照组患者给予干扰素联合羟基脲治疗。观察并比较两组患者的应用效果情况。结果治疗后,两组患者的血液学疗效比较,差异无统计学意义(P>0.05)。观察组患者细胞遗传学疗效优于对照组患者,差异具有统计学意义(P<0.05)。结论伊马替尼与干扰素联合羟基脲治疗慢性粒细胞白血病的临床疗效均较为确切,但伊马替尼在细胞遗传学方面疗效更加确切。

Objective To study the curative effect of imatinib and interferon combined with hydroxyurea for chronic myelogenous leukemia. Methods 68 cases of patients with chronic myelogenous leukemia in our hospital were selected as the study objects and they were randomly divided into observation group and control group. The observation group was treated with imatinib, the control group was treated with hydroxyurea combined with interferon. The application effect between two groups was compared. Results There was no significant difference in hematological efficacy between the two groups after treatment（P 0.05）. The cytogenetic curative effect of the observation group was significantly better than that of the control group, the difference was statistically significant（P0.05）. Conclusion The clinical efficacy of imatinib and interferon combined with hydroxyurea for chronic myelogenous leukemia are both precise, but the effect of imatinib on cell genetics is more exact.